Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
N/A
Address
Description
Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Its Isla101, a drug being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The company was founded by David Foster on May 25, 2020 and is headquartered in Camberwell, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.09
Trade Value (12mth)
AU$2,390.00
1 week
-7.25%
1 month
4.92%
YTD
-27.45%
1 year
-13.85%
All time high
0.62
EPS 3 yr Growth
20.50%
EBITDA Margin
N/A
Operating Cashflow
-$3m
Free Cash Flow Return
-192.20%
ROIC
-173.40%
Interest Coverage
-89.30
Quick Ratio
2.50
Shares on Issue (Fully Dilluted)
98m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
29 August 24 |
Preliminary Final Report
×
Preliminary Final Report |
29 August 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
27 August 24 |
Phase 2a/b clinical trial update
×
Phase 2a/b clinical trial update |
07 August 24 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
07 August 24 |
ISLA-101 Phase 2a/b clinical trial progresses
×
ISLA-101 Phase 2a/b clinical trial progresses |
31 July 24 |
Quarterly Activities & Cashflow Report
×
Quarterly Activities & Cashflow Report |
19 July 24 |
Resignation of Joint Company Secretary
×
Resignation of Joint Company Secretary |
10 July 24 |
Investor Presentation - Bioshares
×
Investor Presentation - Bioshares |
03 July 24 |
Non-binding term sheet signed with BioCryst
×
Non-binding term sheet signed with BioCryst |
03 July 24 |
ISLA-101 Clinical Program Update
×
ISLA-101 Clinical Program Update |
01 July 24 |
Trading Halt
×
Trading Halt |
26 June 24 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
26 June 24 |
Change of Director Interest Notice - DF
×
Change of Director Interest Notice - DF |
21 June 24 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
21 June 24 |
Change in substantial holding
×
Change in substantial holding |
19 June 24 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
12 June 24 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
06 June 24 |
Notification regarding unquoted securities - ILA
×
Notification regarding unquoted securities - ILA |
06 June 24 |
Piggy Back Options Closing Date Reminder
×
Piggy Back Options Closing Date Reminder |
05 June 24 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
03 June 24 |
New data leads to proposed ISLA-101 Phase 2 efficiencies
×
New data leads to proposed ISLA-101 Phase 2 efficiencies |
03 June 24 |
Investor Presentation
×
Investor Presentation |
29 May 24 |
Application for quotation of securities - ILA
×
Application for quotation of securities - ILA |
08 May 24 |
Grant funding to directly support Phase 2a trial
×
Grant funding to directly support Phase 2a trial |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.